Skip to main content
SpringerLink
Log in

FDA warns of serious prostate cancer with 5-αRIs

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. FDA.FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer. Internet Document: [2 pages], 10 Jun 2011. Available from: URL: http://www.fda.gov

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

FDA warns of serious prostate cancer with 5-αRIs. React. Wkly. 1356, 3 (2011). https://doi.org/10.2165/00128415-201113560-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201113560-00007

Keywords

Search

Navigation